ۡ >  ޾ >   >  ץݥܤ󴵼Ԥϡޥեݥνκȯ
ץݥܤ󴵼Ԥϡޥեݥνκȯ ҥå
2019-2-2 7:53 : Mashi () [ 363hit ]

   2018ǯΥΡ٥ءؾޤϡȱ֥åݥ˳ҤȯȤŤؤαѡפˤܽͤΤ餬ޤޤT˦ȯƤPD-1ʬҤϡT˦ȱֱ椷Ƥޤ˦PD-1ʬҤ˷礹ꥬPD-L1ͭT˦PD-1˷礹̡T˦εǽ졢˦Ƥޤޤʿ޻ȡˡΰʤǤ륪ץݥܡʰ̾˥ܥޥ֡ˤϡPD-1PD-L1η˳T˦˦˲Ǥ褦ˤȱ֥åݥ˳Ǥʿ޻ȡˡ


   ȱ֥åݥ˳Ǥ륪ץݥܤϡ2014ǯ˺ڽǽФȱˡȤݸŬǧ줿Τ٤󡢰ߤ󡢥ۥѼ𡢿պ˦ʤɡ¿ΤؤŬ礬ǧ졢¿Τ󴵼ԤͿƤޤʤ顢μŸ̤30%ǤꡢɤΤ褦ʴԤ˸̤ΤŸ̤ͽ¬븡ˡϤΤ褯ʬޤǤ


   Ƕᡢرطϸʤ±ʤθ楰롼פϡڽǽǤ륪ץݥܡʥ˥ܥޥ֡ˤѤȱˡˤơμŸ̤ͽ¬븡ˡ𤷤ƤޤθϡμŸͽ¬ҤǤϤȯǤꡢͿ3ܤˤ륪ץݥܤμŸ̤Ϳ6ܤˤͽ¬Ǥ뤽Ǥ


   θǤϡڽǽ𴵼ԤˤơץݥͿϻͿ6 ܤηβѥ CD163CD163ñޤϥޥեǤΤȯƤإ⥰ӥ󥹥٥󥸥㡼ΤǤٶݤФǧΤȤƤΤƤޤˤ¬塢Ϳ3ܤˤ뼣Ÿ̤ǤʤɤdzǧޤCD163 ϼȼޥեʼϢޥեȤ⤤ȿ˿ᡦѤƤޥեǡϤȱŪƯȹͤƤޤˤΤۤȤɤ˴ޤޤޤޥեȲ CD163 ȤƷФޤ


    CD163 徺롼פǤŪΨ 85%59 50 ˤǥץݥܤμŸ̤줿ΤФߤ⤷Ѳʤä롼פǤŪΨ 87%59 51 ˤǸ̤ϸޤǤץݥܤˤ밭μŤˤơޥեݥФ CD163 ϡμŸͽ¬ҤǤ뤳Ȥǽ餫ˤʤޤCD163ХޡȤƻѤ뤳ȤǡץݥܤˤȱˡκŬǽȤʤǽޤޥեݥǽפƯ򤷤ƤǽŦǽפǤ


   ̤ԹǾܺ٤Ͼʤޤȱ֥åݥ˳ˤޥեݥνGordonˤäƤǶ𤵤ƤޤȼޥեݥPD-1ʬҤäƤ뤿ᡢȱ֥åݥ˳ˤޥեݥ˴ͿƤȤʸǤ餯˦ſ̤ɬפʥƥåפȤʤäƤȻפޤΤǻ˦ǤΤϡѵǤϤʤƥޥեݥǤ顣ȱ֤ˤޥեݥνκȯǤ(by Mashi)


ʸTaku Fujimura et al., Serum level of soluble CD163 may be a predictive marker of the effectiveness of nivolumab in patients with advanced cutaneous melanoma. Frontiers in Oncology2018  doi: 10.3389/fonc.2018.00530  Gordon S.R. et al., PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature (2017) 545(7655):495-499.  doi: 10.1038/nature22396.
 )
ȱ֥åݥ˳ˤȼޥեݥν
ȱ֥åݥ˳ˤȼޥեݥν
ƥڡư ( 295  )     1 ..  11  12  13  14  15  16  17  .. 295    
GNavi   (based on MyAlbum-P)